KR20240052765A - 라디프로딜의 제형 - Google Patents

라디프로딜의 제형 Download PDF

Info

Publication number
KR20240052765A
KR20240052765A KR1020247007585A KR20247007585A KR20240052765A KR 20240052765 A KR20240052765 A KR 20240052765A KR 1020247007585 A KR1020247007585 A KR 1020247007585A KR 20247007585 A KR20247007585 A KR 20247007585A KR 20240052765 A KR20240052765 A KR 20240052765A
Authority
KR
South Korea
Prior art keywords
composition
total weight
pharmaceutically acceptable
weight
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247007585A
Other languages
English (en)
Korean (ko)
Inventor
마리 게닌
피에란드레아 무글리아
Original Assignee
그린 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그린 테라퓨틱스 인코포레이티드 filed Critical 그린 테라퓨틱스 인코포레이티드
Publication of KR20240052765A publication Critical patent/KR20240052765A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247007585A 2021-08-06 2022-08-05 라디프로딜의 제형 Pending KR20240052765A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163230331P 2021-08-06 2021-08-06
US63/230,331 2021-08-06
PCT/US2022/039543 WO2023014956A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Publications (1)

Publication Number Publication Date
KR20240052765A true KR20240052765A (ko) 2024-04-23

Family

ID=83189017

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007585A Pending KR20240052765A (ko) 2021-08-06 2022-08-05 라디프로딜의 제형

Country Status (12)

Country Link
US (2) US20250127770A1 (https=)
EP (1) EP4380547A1 (https=)
JP (1) JP2024529185A (https=)
KR (1) KR20240052765A (https=)
CN (1) CN118019521A (https=)
AU (1) AU2022323381A1 (https=)
CA (1) CA3228004A1 (https=)
CO (1) CO2024002715A2 (https=)
IL (1) IL310652A (https=)
MX (1) MX2024001744A (https=)
PE (1) PE20241385A1 (https=)
WO (1) WO2023014956A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137652A2 (en) * 2023-12-20 2025-06-26 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453383C (en) 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Piperidine derivatives as nmda receptor antagonists
CA2730253A1 (en) * 2008-07-08 2010-01-14 Alphonso Higuera Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
AU2009282822A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating CNS disorders
HUP0900130A3 (en) * 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US8328687B2 (en) 2010-07-09 2012-12-11 Ford Global Technologies, Llc Method for controlling an engine that may be automatically stopped

Also Published As

Publication number Publication date
CO2024002715A2 (es) 2024-05-20
IL310652A (en) 2024-04-01
US20250127770A1 (en) 2025-04-24
WO2023014956A1 (en) 2023-02-09
AU2022323381A1 (en) 2024-03-21
JP2024529185A (ja) 2024-08-01
EP4380547A1 (en) 2024-06-12
US20260053786A1 (en) 2026-02-26
PE20241385A1 (es) 2024-07-09
CA3228004A1 (en) 2023-02-09
WO2023014956A9 (en) 2023-12-14
CN118019521A (zh) 2024-05-10
MX2024001744A (es) 2024-04-23

Similar Documents

Publication Publication Date Title
EP1511481B1 (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye
EP2258394B1 (en) Oral dosage form comprising a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
JP2022084651A (ja) 新規組成物および方法
US20260053786A1 (en) Formulations of radiprodil
CN101597272B (zh) 艾拉莫德的钾盐化合物,其制备方法和药物应用
KR20150139501A (ko) 안과용 제형
TW202345842A (zh) Ｐｒｏｔａｃ化合物之醫藥組合物及其用途
EP3302477B1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
WO2017054741A1 (zh) 提高索拉非尼生物利用度的制剂
WO2023129649A1 (en) Pharmaceutical composition
EA023294B1 (ru) Фармацевтическая композиция, содержащая солифенацин
CA3196482A1 (en) Jak inhibitors having a specific particle size distribution
TW202515524A (zh) 布洛芬藥物組合物、其製備方法及用途
CN121866060A (zh) 用于混悬剂制剂的新型组合物
CN104826120A (zh) 波生坦的制剂
CN104306331A (zh) 一种盐酸西替利嗪糖浆
US10183018B2 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
AU2020315214B2 (en) Pharmaceutical composition of temozolomide.
JP2018145182A (ja) 医薬組成物
CN110582278A (zh) 药物组合物及其用途
US20200179372A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
AU2007216671A1 (en) Pleasant-tasting ranitidine formulation
CN114222565B (zh) 一种药物组合物
RU2848179C2 (ru) Инъекционная депо-форма, содержащая частицы свободного основания карипразина
US12419881B1 (en) Methods of using radiprodil in the treatment of disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application